KONEXElectrical Equipment199290

Bio Protech

₩447 0.00%2026-11-18 close
Market Cap
₩7.8B
Turnover
₩0
Volume
0 shares
Shares out.
17.5M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Operating gains, but net losses persist

Operating profit rose in 2025, but a heavier non-operating cost burden turned the bottom line into a net loss and pushed standalone equity below zero.

  1. 1

    Fiscal 2025 revenue reached KRW 31.1 billion, up about 24% from 2024 (JobKorea financial data).

  2. 2

    Operating profit grew from KRW 0.2 billion in 2024 to KRW 1.3 billion in 2025, an improvement at the operating level.

  3. 3

    Non-operating costs swelled to about KRW 6.1 billion, producing a KRW 2.2 billion net loss in 2025 after a similar-sized profit in 2024.

  4. 4

    Standalone equity fell from about KRW 6.0 billion at end-2024 to about negative KRW 1.7 billion at end-2025, a state of full capital impairment.

  5. 5

    Over the same period, KONEX biotech companies saw revenue rise 9.0%, yet operating and net losses continued across the sector.

02

Business structure

BIO Protech is a medical device maker founded in May 2000, with its headquarters and production plant in Wonju, Gangwon State. Its core products are ECG electrodes for cardiac monitoring and electrodes for transcutaneous electrical nerve stimulators (TENS).

Its patent and trademark records also cover electrosurgical smoke pencils, SpO2 oxygen-saturation sensors, and electrodes for automated external defibrillators, so the range spans both electrodes and sensors.

The core material is conductive hydrogel, which is used across several electrode products including ECG electrodes and high-frequency surgical grounding pads. The company said it independently developed the hydrogel in 2013, which lowered costs and raised production efficiency.

Manufacturing relies on automated equipment, and the company presents this as the basis of its production competitiveness. In 2003 BIO Protech set up a US subsidiary, Bio Protech U.S.A Inc., to establish an overseas base.

The company's own business profile says the medical device market is expected to keep growing on aging populations and rising health awareness. Competitive differentiation is presented mainly around its in-house hydrogel materials and automated production.

03

Recent trends

Revenue for fiscal 2025 reached KRW 31.1 billion, up about 24% from 2024, according to JobKorea's compiled financial data. Operating profit rose from KRW 0.2 billion in 2024 to KRW 1.3 billion in 2025, showing improvement at the operating level.

Non-operating costs grew to about KRW 6.1 billion, and the company posted a net loss of KRW 2.2 billion after a net profit of similar size in 2024. On a standalone basis compiled by FnGuide from DART filings, 2024 revenue was KRW 25.1 billion, operating profit KRW 0.2 billion, and net profit KRW 2.2 billion.

Standalone equity moved from about KRW 6.0 billion at end-2024 to about negative KRW 1.7 billion at end-2025, a state of full capital impairment. Paid-in capital declined from about KRW 11.2 billion to about KRW 8.7 billion over the same period.

The fiscal 2025 annual report was filed on March 23, 2026, with a corrected filing on March 30, 2026. At the annual general meeting on March 31, 2026, shareholders approved the fiscal 2025 financial statements and reappointed the external auditor.

According to Korea Exchange data for December-year-end KONEX companies, biotech sector revenue rose 9.0% in 2025, while losses persisted. As of 2:10 a.m. KST on November 11, 2026, the share price was KRW 400, unchanged from the prior session, with trading value of KRW 58,200.

04

Outlook

The direction of future net losses will largely depend on whether non-operating costs prove one-off or recurring in nature. Operating profit moved from KRW 0.6 billion in 2023 to KRW 0.2 billion in 2024 and KRW 1.3 billion in 2025, so whether operating-level improvement continues is the first checkpoint.

While standalone equity remains negative, the pace of capital recovery becomes the central gauge of financial stability. The company filed a corrected material-event report on a convertible bond issuance decision dated May 15, 2025, and convertible bonds can increase the share count if converted.

Across a KONEX biotech sector that is still posting losses, the comparison point is how the company's results diverge from sector trends. Whether thin trading volume persists is also a liquidity indicator to keep following.

The next periodic filing is the third-quarter 2026 report, due by November 14, 2026, which will show cumulative 2026 operating profit and the trend in non-operating items. Demand for medical devices tied to aging populations remains a medium-term background factor for revenue.

The company is currently in a phase where operating indicators are improving while the financial structure is weakening.

05

Bull factors

Operating profit recovery

Operating profit fell from KRW 0.6 billion in 2023 to KRW 0.2 billion in 2024 before rising to KRW 1.3 billion in 2025. Operating profit growth alongside higher revenue of KRW 31.1 billion is cited as the bull-case basis. Whether this trend holds after 2026 is the premise of the bullish argument.

Hydrogel-based technology assets

A conductive hydrogel patent was registered in 2012, and the company also holds a patent for a wet-gel electrode manufacturing apparatus and several trademarks. The hydrogel is applied across ECG electrodes, TENS electrodes, and high-frequency grounding pads. The company said its independent development in 2013 produced cost savings.

Demand tied to aging populations

The company's business profile says the medical device market is expected to keep growing on aging populations and rising health awareness. ECG electrodes are a product group directly linked to diagnostic and monitoring demand among older patients. This demand structure is a medium-term revenue foundation rather than a short-term driver.

06

Bear factors

Non-operating costs drive a net loss

Non-operating costs of about KRW 6.1 billion in 2025 far exceeded operating profit of KRW 1.3 billion. The result was a KRW 2.2 billion net loss, a reversal from the KRW 2.2 billion net profit in 2024. If these costs recur, operating improvement may struggle to reach the bottom line.

Standalone capital impairment and borrowing burden

Standalone equity fell from about KRW 6.0 billion in 2024 to about negative KRW 1.7 billion in 2025. Under full capital impairment, access to borrowing and working capital financing may be constrained. JobKorea's compiled data put the borrowings dependency ratio at 73.58% in 2025.

Sector losses and thin trading

According to Korea Exchange data, KONEX biotech companies posted a 9.0% revenue rise in 2025 but continued to report operating and net losses. The company's trading value of KRW 58,200 indicates very low liquidity. In such a market, prices can be driven by small volumes.

07

Risk factors

Macro

If interest rates stay high, borrowing costs and convertible bond interest could raise non-operating expenses further. Raw material and logistics cost swings could also weigh on manufacturing costs. Exchange-rate moves may affect overseas results through the US subsidiary.

Regulatory

Medical devices are subject to product approvals, certifications, and reimbursement changes that can reshape revenue. Given the US subsidiary, overseas regulatory shifts are also a factor to weigh. Because the product line is concentrated in electrodes, sensitivity to specific policy changes may be high.

Liquidity

As a KONEX-listed company with small trading value, price moves can be driven by modest volume. At a market capitalization of about KRW 7.0 billion, small trades can move quotes. Low liquidity tends to limit participation by large institutional investors.

08

Overall view

BIO Protech grew both revenue and operating profit in 2025, but rising non-operating costs produced a net loss of KRW 2.2 billion. Standalone equity fell to about negative KRW 1.7 billion, a state of full capital impairment, and the borrowings dependency ratio was reported at a high level.

Bullish factors cited include the operating profit recovery, hydrogel-based technology, and demand tied to aging populations. Bearish factors include the swing to a net loss, capital impairment, and low trading liquidity.

Because KONEX biotech companies as a group continue to post losses, the key interpretive question is how much of the result reflects company-specific versus sector factors. Capital recovery and whether non-operating items recur are the central variables for the financial picture. The next checkpoint is the non-operating income and equity movements in the third-quarter 2026 report.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 8 more articles and sources
  1. comp.fnguide.com
  2. jobkorea.co.kr
  3. kind.krx.co.kr
  4. m.irgo.co.kr
  5. englishdart.fss.or.kr
  6. news.nate.com
  7. newspim.com
  8. m.news.nate.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis